(18) proved that HuR protein may be a useful target for the screening of anti-tumor angiogenesis drugs, as they found that a compound ZM-32 could effectively prevent the formation of HuR RRM1/2–VEGFA mRNA complex, thus suppressing the proliferation, migration, growth, and angiogenesis of breast cancer cells. The gene discussed is ELAVL1; the disease is breast carcinoma.